Insights

The Hatch-Waxman Act was supposed to make generic pharmaceuticals a reliable business. File an Abbreviated New Drug Application (ANDA), prove […]

The ‘grand bargain’ of pharmaceutical patents is one of the most consequential, most contested, and most misunderstood arrangements in modern

The rivalry between India and China in pharmaceuticals is the most consequential industrial contest of the next decade. It will

Patent litigation is where drug revenue is won or lost. For a blockbuster product generating $5 billion annually, a single

Every five years or so, the pharmaceutical industry rediscovers the patent cliff as though it is a new emergency. It

Every major pharmaceutical revenue event, from a blockbuster’s first generic competitor to a biosimilar’s delayed U.S. launch, traces back to

The single most valuable regulatory asset in the U.S. generic pharmaceutical industry is not a patent. It is the absence

Part I: The Architecture of Pharmaceutical Value — Patents as Financial Instruments What a Drug Patent Actually Is (And What

The $236 billion Loss of Exclusivity wave hitting between 2025 and 2030 is the most concentrated revenue erosion event in